[HTML][HTML] EASL Clinical Practice Guidelines: management of hepatitis C virus infection
European Association For The Study Of The Liver - Journal of hepatology, 2014 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide. The long-term impact of HCV infection is highly variable, from minimal changes …
worldwide. The long-term impact of HCV infection is highly variable, from minimal changes …
EASL recommendations on treatment of hepatitis C 2014
European Association for The Study of The Liver - Journal of Hepatology, 2014 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
EASL recommendations on treatment of hepatitis C: final update of the series☆
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
EASL recommendations on treatment of hepatitis C 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
[HTML][HTML] EASL recommendations on treatment of hepatitis C 2015
European Association For The Study Of The Liver - Journal of hepatology, 2015 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
[引用][C] Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
AASLD/IDSA HCV Guidance Panel, RT Chung… - …, 2015 - Wiley Online Library
The pace of hepatitis C virus (HCV) drug development in recent years has accelerated
dramatically. For patients to benefit from these impressive advances, practitioners need …
dramatically. For patients to benefit from these impressive advances, practitioners need …
EASL recommendations on treatment of hepatitis C 2016
European Association for The Study of The Liver - Journal of hepatology, 2017 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
[PDF][PDF] Diagnosis, management, and treatment of hepatitis C: an update
Background The hepatitis C virus (HCV) is a major public health problem and a leading
cause of chronic liver disease. 5 An estimated 180 million people are infected worldwide. 6 …
cause of chronic liver disease. 5 An estimated 180 million people are infected worldwide. 6 …
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
C Welsch, A Jesudian, S Zeuzem, I Jacobson - Gut, 2012 - gut.bmj.com
Until recently, the standard of care (SOC) for patients with chronic hepatitis C virus (HCV)
infection has consisted of a combination of pegylated interferon-N1 plus ribavirin …
infection has consisted of a combination of pegylated interferon-N1 plus ribavirin …
Hepatitis C guidance 2023 update: american association for the study of liver diseases–infectious diseases society of america recommendations for testing, managing …
D Bhattacharya, A Aronsohn, J Price… - Clinical Infectious …, 2023 - academic.oup.com
Abstract The Infectious Diseases Society of America and the American Association for the
Study of Liver Diseases have collaboratively developed evidence-based guidance …
Study of Liver Diseases have collaboratively developed evidence-based guidance …